摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-氟-6-羟基吡啶 | 50543-23-2

中文名称
2-氟-6-羟基吡啶
中文别名
6-氟吡啶-2-醇;6-氟吡啶-2(1H)-酮;2-羟基-6-氟吡啶
英文名称
2-fluoro-6-hydroxypyridine
英文别名
6-fluoro-2-hydroxypyridine;6-fluoro-1H-pyridin-2-one
2-氟-6-羟基吡啶化学式
CAS
50543-23-2
化学式
C5H4FNO
mdl
——
分子量
113.091
InChiKey
AJRUXHIEYSYRQJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    125-129℃
  • 沸点:
    273.1±40.0 °C(Predicted)
  • 密度:
    1.26±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    8
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    29.1
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 危险等级:
    IRRITANT
  • 危险品标志:
    Xn
  • 危险类别码:
    R22
  • 海关编码:
    2933399090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:c4dfc8f4e46714677e13bb6b68ab4d3f
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-Fluoro-6-hydroxypyridine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

Section 3. Composition/information on ingredients.
Ingredient name: 2-Fluoro-6-hydroxypyridine
CAS number: 50543-23-2

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C5H4FNO
Molecular weight: 113.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    2-氟-6-羟基吡啶tetraphosphorus decasulfide 作用下, 以 甲苯 为溶剂, 反应 18.0h, 以23.7%的产率得到2-fluoro-6-[(6-fluoropyridin-2-yl)disulfanyl]pyridine
    参考文献:
    名称:
    Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
    摘要:
    本发明涉及一种具有以下化学式I的化合物: 或其药用可接受的盐,其中R 1 ,R 2 ,R 3 ,W,X,Y,Z,n,o,p和q在此处定义,用于治疗CFTR介导的疾病,如囊性纤维化。本发明还涉及药物组合物、治疗方法和相关工具包。
    公开号:
    US20160095858A1
  • 作为产物:
    描述:
    2,6-二氟吡啶 、 potassium hydroxide 作用下, 以 1,4-二氧六环 为溶剂, 反应 114.0h, 以62%的产率得到2-氟-6-羟基吡啶
    参考文献:
    名称:
    通过金属催化的交叉偶联方法发散合成芳基化吡啶-2(1 H)-one衍生物
    摘要:
    从2-氟-5-吡啶基硼酸开始容易地以高收率获得1,5-二(杂)芳基化吡啶-2-2(1 H)-one衍生物。该序列包括三个步骤:(i)钯催化的Suzuki-Miyaura反应;(ii)碱催化水解;(iii)铜催化的C–N耦合。报告了选定的吡啶-2(1 H)-one衍生物的X射线晶体结构。这些化合物作为用于药物发现的新支架是令人感兴趣的。
    DOI:
    10.1016/j.tet.2010.05.108
点击查看最新优质反应信息

文献信息

  • Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
    申请人:VERTEX PHARMACEUTICALS INCORPORATED
    公开号:US20160095858A1
    公开(公告)日:2016-04-07
    The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
    本发明涉及一种具有以下化学式I的化合物: 或其药用可接受的盐,其中R 1 ,R 2 ,R 3 ,W,X,Y,Z,n,o,p和q在此处定义,用于治疗CFTR介导的疾病,如囊性纤维化。本发明还涉及药物组合物、治疗方法和相关工具包。
  • TYK2 INHIBITORS AND USES THEREOF
    申请人:Nimbus Lakshmi, Inc.
    公开号:US20160251376A1
    公开(公告)日:2016-09-01
    The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
    本发明提供了化合物、其组合物以及使用这些化合物来抑制TYK2并治疗TYK2介导的疾病的方法。
  • Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer
    作者:Ming He、Wentao Ning、Zhiye Hu、Jian Huang、Chune Dong、Hai-Bing Zhou
    DOI:10.1016/j.ejmech.2020.112281
    日期:2020.6
    dual-targeting drugs has become a new strategy. In this study, we have developed a series of dual-acting agents targeting both estrogen receptor α (ERα) and histone demethylase based on a privileged OBHS pharmacophore scaffold developed previously by our laboratory. These novel OBHS-LSD1i conjugates showed excellent ERα binding affinity and selectivity, and exhibited potent inhibitory activity against lysine
    乳腺癌是一种多因素疾病,因此越来越多的药物联合疗法被用于治疗。但是,药物联合治疗存在不可否认的缺点。因此,开发新型的双重靶向药物已经成为一种新的策略。在这项研究中,我们基于实验室先前开发的OBHS药效基团支架,开发了一系列针对雌激素受体α(ERα)和组蛋白脱甲基酶的双作用剂。这些新颖的OBHS-LSD1i共轭物表现出优异的ERα结合亲和力和选择性,并表现出对赖氨酸特异性脱甲基酶1(LSD1)的有效抑制活性。与4-羟基他莫昔芬体外相比,几种缀合物在MCF-7乳腺癌细胞系中显示出更高的抗增殖功效。其中,最佳化合物11g对LSD1和MCF-7细胞表现出有效的抑制活性,IC50值分别为1.55μM和8.79μM。流式细胞术分析11g的凋亡表明这种类型的化合物对MCF-7细胞的影响部分是由诱导凋亡引起的。而且,11g与ERα的分子对接以及LSD1 / CoREST配合物的活性位点为理解这类化合物与靶
  • Chemoselective <i>N</i>- and <i>O</i>-Difluoromethylation of 2-Pyridones, Isoquinolinones, and Quinolinones with TMSCF<sub>2</sub>Br
    作者:Ziyue Zhu、Vinayak Krishnamurti、Xanath Ispizua-Rodriguez、Colby Barrett、G. K. Surya Prakash
    DOI:10.1021/acs.orglett.1c02305
    日期:2021.8.20
    An operationally simple protocol for direct N- and O-difluoromethylation of 2-pyridones, quinolinones, and isoquinolinones using commercially available TMSCF2Br is disclosed. The chemoselectivity is modulated by simple variations in temperature, solvent, and strength of the base. Diverse, synthetically relevant functional groups are tolerated, including functional groups that have reported reactivity
    公开了使用可商购的 TMSCF 2 Br直接对 2-吡啶酮、喹啉酮和异喹啉酮进行N-和O-二氟甲基化的操作简单的方案。化学选择性通过温度、溶剂和碱强度的简单变化来调节。可以耐受多种合成相关的官能团,包括已报告与 TMSCF 2 Br反应的官能团。包括制备N - 和O - 二氟甲基化合物的克级反应。
  • 6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors
    作者:Patrick Sarver、Michael Acker、Jeffrey T. Bagdanoff、Zhouliang Chen、Ying-Nan Chen、Homan Chan、Brant Firestone、Michelle Fodor、Jorge Fortanet、Huaixiang Hao、Murphy Hentemann、Mitsunori Kato、Robert Koenig、Laura R. LaBonte、Gang Liu、Shumei Liu、Chen Liu、Eric McNeill、Morvarid Mohseni、Martin Sendzik、Travis Stams、Stan Spence、Victoriano Tamez、Ritesh Tichkule、Christopher Towler、Hongyun Wang、Ping Wang、Sarah L. Williams、Bing Yu、Matthew J. LaMarche
    DOI:10.1021/acs.jmedchem.8b01726
    日期:2019.2.28
    phosphatase SHP2 is an oncoprotein associated with cancer as well as a potential immune modulator because of its role in the programmed cell death PD-L1/PD-1 pathway. In the preceding manuscript, we described the optimization of a fused, bicyclic screening hit for potency, selectivity, and physicochemical properties in order to further expand the chemical diversity of allosteric SHP2 inhibitors. In this
    蛋白质酪氨酸磷酸酶SHP2是与癌症相关的癌蛋白,也是一种潜在的免疫调节剂,因为它在程序性细胞死亡PD-L1 / PD-1途径中发挥了作用。在前面的手稿中,我们描述了针对功效,选择性和理化特性的融合双环筛选命中方法的优化,以进一步扩大变构SHP2抑制剂的化学多样性。在本手稿中,我们描述了我们方法的进一步扩展,通过对SAR的理解和基于结构的设计,将融合的双环系统转变为新型的单环嘧啶酮支架。这些研究导致了对SHP394(1)的鉴定,SHP394是一种口服有效的SHP2抑制剂,具有高亲脂性,增强的药效和增强的药代动力学特性。我们还报告了其他具有良好药代动力学和药效学特征的嘧啶酮类似物。总体而言,这项工作改进了我们先前描述的变构抑制剂,并举例说明并扩展了通过变构机理抑制SHP2的允许化学模板的范围。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-